Akero shares soar as NASH drug succeeds in mid-stage trial | BioPharma Dive

Retrieved on: 2022-09-14 02:55:58

Tags for this article:

Medical specialties

Medicine

Hepatitis

Clinical medicine

RTT

Non-alcoholic fatty liver disease

Click the tags to see associated articles and topics

Akero shares soar as NASH drug succeeds in mid-stage trial | BioPharma Dive. View article details on HISWAI: https://www.biopharmadive.com/news/akero-therapeutics-efruxifermin-nash-study-results/631723/

Excerpt

Akero Therapeutics' shares more than doubled in early trading on Tuesday after the company said an experimental medicine reduced the internal scarring ...

Article found on: www.biopharmadive.com

View Original Article